Dual Stage Venous Cannulae

K263092 · Sorin Group Italia S.R.L. · DWF · Oct 1, 2026 · Cardiovascular

Device Facts

Record IDK263092
Device NameDual Stage Venous Cannulae
ApplicantSorin Group Italia S.R.L.
Product CodeDWF · Cardiovascular
Decision DateOct 1, 2026
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 870.4210
Device ClassClass 2

Indications for Use

The Dual Stage Venous Cannula is indicated for single tube venous drainage from the right atrium and vena cava during cardiopulmonary bypass surgery for up to six hours.

Device Story

Dual Stage Venous Cannulae are single-use, sterile, non-pyrogenic devices used for venous drainage during cardiopulmonary bypass surgery. The device consists of an open-lumen PVC tube with wire reinforcement in the distal section and a malleable obturator for vessel placement. The distal end features a lighthouse-shaped tip and a perforated basket sleeve for fluid intake. The proximal end is clear and non-reinforced to allow for clamping and connection to standard cardiopulmonary bypass tubing, either directly or via a pre-mounted 1/2" barbed connector. The surgeon inserts the cannula into the right atrium and vena cava, removes the obturator, and connects the device to the venous line. The device facilitates blood flow from the patient to the bypass circuit. This submission adds new French size configurations to the existing product line.

Clinical Evidence

No clinical testing was conducted. Substantial equivalence is supported by non-clinical verification and validation testing performed in accordance with ISO 18193, including visual inspection, kink testing, collapse resistance, integrity, pull strength, blood pathway integrity, clamp testing, flow rate/pressure drop analysis, and blood trauma characterization. All tests passed.

Technological Characteristics

Materials: PVC polymer, wire reinforcement. Design: Open-lumen tube with distal lighthouse tip and perforated basket sleeve. Dimensions: Various French sizes (proximal 37-50 Fr, distal 29-36 Fr). Energy: Passive fluid drainage. Connectivity: None. Sterilization: Ethylene oxide. Single-use.

Indications for Use

Indicated for single tube venous drainage from the right atrium and vena cava during cardiopulmonary bypass surgery for up to six hours in adolescents (12-22 years) and adults (22+ years).

Regulatory Classification

Identification

A cardiopulmonary bypass vascular catheter, cannula, or tubing is a device used in cardiopulmonary surgery to cannulate the vessels, perfuse the coronary arteries, and to interconnect the catheters and cannulas with an oxygenator. The device includes accessory bypass equipment.

Predicate Devices

Submission Summary (Full Text)

{1} **U.S. FOOD & DRUG** ADMINISTRATION October 1, 2026 Sorin Group Italia S.R.L. Luigi Vecchi RA Director Via Statale 12 Nord, 86 Mirandola, 41037 Italy Re: K263092 Trade/Device Name: Dual Stage Venous Cannulae Regulation Number: 21 CFR 870.4210 Regulation Name: Cardiopulmonary Bypass Vascular Catheter, Cannula, Or Tubing Regulatory Class: Class II Product Code: DWF Dated: September 3, 2026 Received: September 3, 2026 Dear Luigi Vecchi: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding {2} K263092 - Luigi Vecchi Page 2 When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {3} K263092 - Luigi Vecchi Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, # KATHLEEN M. GRUNDER -S for Nicole Gillette Assistant Director DHT2B: Division of Circulatory Support, Structural, and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {4} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K263092 | ? | | Please provide the device trade name(s). | | ? | | Dual Stage Venous Cannulae | | | | Please provide your Indications for Use below. | | ? | | The Dual Stage Venous Cannula is indicated for single tube venous drainage from the right atrium and vena cava during cardiopulmonary bypass surgery for up to six hours. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☑ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? | {5} LivaNova # 510(k) Summary (in accordance with 21 CFR 807.92) 510(k) Number: K263092 # I. Applicant Information Applicant: SORIN GROUP ITALIA S.R.L. Via Statale 12 Nord, 86 Mirandola, MO 41047 Italy Contact Person: Luigi Vecchi Regulatory Affairs Director Tel: +39 0535 29957 e-mail: luigi.vecchi@livanova.com Application Correspondent: SORIN GROUP ITALIA S.R.L. Via Statale 12 Nord, 86 Mirandola, MO 41047 Italy Contact Person: Luigi Vecchi Regulatory Affairs Director Tel: +39 0535 29957 e-mail: luigi.vecchi@livanova.com Date Prepared: September 30, 2026 ## II. Subject Device Identification Device Trade Name: Dual Stage Venous Cannulae Classification Name: Cardiopulmonary bypass vascular catheter, cannula, or tubing Regulation Number: 21 CFR 870.4210 Product Code: DWF Classification: Class II Classification Panel: Cardiovascular ### III. Predicate Device The Dual Stage Venous Cannulae are substantially equivalent to the following cleared predicate devices: Primary Predicate Device | Venous cannulae | 510(k) Number: | K253671 | | --- | --- | --- | | | Device Trade Name: | Dual Stage Venous Return Cannulae | | | Classification Name: | Cardiopulmonary bypass vascular catheter, cannula, or tubing | | | Regulation Number: | 21 CFR 870.4210 | | | Product Code: | DWF | | | Classification: | Class II | | | Classification Panel: | Cardiovascular | Special 510(k) – Dual Stage Venous cannulae Page 1 {6} LivaNova Secondary Predicate Device | Venous cannulae | 510(k) Number: | K120072 | | --- | --- | --- | | | Device Trade Name: | Edwards Lifesciences venous drainage cannulas | | | Classification Name: | Cardiopulmonary bypass vascular catheter, cannula, or tubing | | | Regulation Number: | 21 CFR 870.4210 | | | Product Code: | DWF | | | Classification: | Class II | | | Classification Panel: | Cardiovascular | #### IV. Device Description Dual Stage Venous Cannulae are single-use, non-toxic, non-pyrogenic fluid path devices and supplied sterile and individually packaged. The devices are composed of the cannula: an open lumen PVC polymer tube incorporating wire reinforcement in distal section. A malleable obturator is inserted into the cannula to allow the placement of the cannula along the vein. Once the cannula is positioned in the vessel the surgeon removes the obturator from the cannula tubing and connects the cannula to the venous line. The distal end of the cannula has a lighthouse-shaped tip, allowing the venous blood to flow from the vessel into the cannula; another open section (identified as basket) allowing the fluids flows from outside into the cannula body is present in the distal section of the cannula where is located a sleeve perforated with multiple holes. The clear proximal section of the cannula is not reinforced to allow clamping; the proximal end typically does not have any pre-mounted connector and can accommodate a barbed connector for standard cardiopulmonary bypass tubing ( \( \frac{1}{2} \) " diameter). In these models of cannulae a version with a pre-mounted 1/2" barbed connector is also available. The Dual Stage Venous Cannulae are the modified version of the disposables currently marketed under K253671; specifically with this submission, the cannula size with 29 Fr Distal and 37 Fr proximal diameter has been added. In total the following cannula models are available: | Device trade name | Model | French size (Outside diameter) | Characteristics | | --- | --- | --- | --- | | Dual Stage Venous Cannulae | RDS-61037 | Proximal: 37 FrDistal: 29 Fr. | Without connector | | Dual Stage Venous Cannulae | RDS-61040 | Proximal: 40 FrDistal: 32 Fr. | Without connector | | Dual Stage Venous Cannulae | RDS-61034 | Proximal: 46 FrDistal: 34 Fr. | Without connector | | Dual Stage Venous Cannulae | RDS-61046 | Proximal: 46 FrDistal: 36 Fr. | Without connector | | Dual Stage Venous Cannulae | RDS-61137 | Proximal: 37 FrDistal: 29 Fr. | With connector | | Dual Stage Venous Cannulae | RDS-61140 | Proximal: 40 FrDistal: 32 Fr. | With connector | | Dual Stage Venous Cannulae | RDS-61134 | Proximal: 46 FrDistal: 34 Fr. | With connector | | Dual Stage Venous Cannulae | RDS-61146 | Proximal: 46 FrDistal: 36 Fr. | With connector | | Dual Stage Venous Cannulae | RDS-61150 | Proximal: 50 FrDistal: 36 Fr. | With connector | Special 510(k) – Dual Stage Venous cannulae Page 2 {7} LivaNova # V. Indications for Use The Dual Stage Venous Cannula is indicated for single tube venous drainage from the right atrium and vena cava during cardiopulmonary bypass surgery for periods up to six hours. The proposed patient population is Adults and Adolescents. # VI. Summary of Technical Characteristics The Dual Stage Venous Cannulae have the same fundamental technological characteristics, principles of operation and control mechanisms as the predicate unmodified devices. Both subject and predicate devices are recommended for use as Venous cannula during cardiopulmonary bypass for periods up to six hours. The devices are ethylene oxide sterilized and have a non-pyrogenic fluid path. They are for single use only. # VII. Non-Clinical Performance Data Sorin Group Italia has conducted extensive verification and validation testing of the Venous Cannulae; specifically, the following tests in accordance with ISO18193 were carried out: - Visual inspection - Label legibility and marking durability - Cannula kink test - Drainage cannula collapse resistance - Cannula integrity - Pull strength - Blood pathway integrity - Cannula clamp test - Flow rate and pressure drop through cannulae - Blood trauma characterization test The devices passed all the testing in accordance with the above-mentioned standard. # VIII. Clinical Performance Data No clinical testing was conducted in support of the Dual Stage Venous Cannulae. The indications for use and technical characteristics are equivalent to those of the predicate devices. The non-clinical testing summarized in this submission supports the substantial equivalence of the subject devices with the predicate devices when used according to their intended use. # IX. Statement of Substantial Equivalence Based on equivalent intended use and technological characteristics, the Dual Stage Venous Cannulae can be deemed to be substantially equivalent to their predicate devices: - the unmodified LivaNova Dual Stage Venous Return Cannulae, cleared under K253671; - the Edwards Lifesciences Venous drainage cannulae, cleared under K120072 The Dual Stage Venous Cannulae, as designed and manufactured, do not raise new questions regarding safety and effectiveness and are determined to be substantially equivalent to their predicate devices. Special 510(k) – Dual Stage Venous cannulae Page 3
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...